In UAE 40% of all cancers are breast cancer this why addressing this cancer is so crucial. CDK4/6 inhibitors are a class of drugs used to treat certain types of hormone receptor-positive, HER2-negative breast cancer. More than two out of every three breast cancers are both hormone receptor-positive and HER2-negative. Those drugs work by preventing the CDK4 and CDK6 proteins from catalyzing the phosphorylation of specific targets, thus preventing cell growth and proliferation in order to slow or even stop the cancer cells from growing. Currently there are three CDK4/6 inhibitors used to treat breast cancer: palbociclib, ribociclib and abemaciclib.
Dr. Hassan Ghazal practices at King’s College Hospital, Dubai. He is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist. He has been involved in numerous clinical trials in the US, serving as Principal Investigator, for over 25 years.